SI
AZN icon

Sofinnova Investments’s AstraZeneca AZN Stock Holding History

Sofinnova Investments’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-96,700
Closed -$7.65M – 61
2018
Q3 		$7.65M Buy
+96,700
New +$7.31M 0.68% 28

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Sofinnova Investments's AZN Position: Q1 2026 in Review

Sofinnova Investments reduced its AstraZeneca (AZN) stake by 44% in Q1 2026, selling an estimated $69.4M and leaving 456,031 shares worth $89.9M. The position accounts for 3.42% of the portfolio, ranked #8.

Sofinnova Investments first reported a position in AZN in Q1 2018 and has held it in 24 quarters since. The position peaked at $150M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Sofinnova Investments held 456,031 shares of AstraZeneca worth $89.9M as of Q1 2026.
  • Sofinnova Investments sold 360,136 AstraZeneca shares in Q1 2026, an estimated $69.4M.
  • AstraZeneca made up 3.42% of Sofinnova Investments's portfolio in Q1 2026, its #8 holding.
  • Sofinnova Investments first reported a position in AstraZeneca in Q1 2018 and has held it in 24 quarters since.
  • Sofinnova Investments's AstraZeneca position peaked at $150M in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.